Response to viscosupplementation with HAppyCross in hip OA: Discover the results in our published article
Predictors of response to viscosupplementation in patients with hip osteoarthritis: results of a prospective, observational, multicentre, open-label, pilot study. Eymard et al. BMC Musculoskeletal Disorders (2017) 18:3. DOI 10.1186/s12891-016-1359-2.
- Prospective, observational, multicentre, open-label study:
- 100 hip OA
- 59 men /41 women; mean age 62 (36-87)
- BMI 25,4 (17,9-41,8)
- 1 injection of HANOX-M-XL(HAppyCross®) under US or fluoroscopy
- Population ITT: 100, PP: 90
- Outcome measures:
- WOMAC pain and function scores as well as patient global assessment (PGA) were assessed at baseline and day 90
- Improvement, satisfaction and efficacy were self-assessed at day 90
- Predictors of response:
- All outcome measures improved significantly between D0 and D90 (P<0.0001).
- 80% of patients considered them as « improved ».
- 48% were RESPONDERS (improvement >50%)
Read Full Text